Skip to main content

Table 1 Laboratory findings before treatment

From: Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report

Item Value Item Value Item Value
AST 51 IU/L BUN 16 mg/dL HBsAg negative
ALT 66 IU/L Creatinine 0.68 mg/dL Anti-HCV positive
LDH 256 IU/L UA 4.3 mg/dL HCV RNA 6.4 logIU/mL
ALP 96 IU/L Na 136 mEq/L HCV genotype 2b
γ-GTP 88 IU/L K 3.9 mEq/L Anti-HIV negative
T. Bil 1.2 mg/dL Cl 104 mEq/L Hyaluronic acid 37 ng/mL
TP 7.1 g/dL WBC 5900/μL AFP 7.4 ng/mL
Albumin 3.9 g/dL RBC 477 × 104/μL PIVKA-II 32 mAU/mL
Amylase 83 IU/L Hemoglobin 14.4 g/dL NH3 58 μg/dL
CPK 102 IU/L Haematocrit 40.7 % HbA1c 7.8 %
T.CHO 115 mg/dL Platelets 15.6 × 104/μL CRP 0.1 mg/dL
TG 103 mg/dL PT 100 %   
  1. AFP α-Fetoprotein, ALP alkaline phosphatase, BUN blood urea nitrogen, CPK creatine phosphokinase, CRP C-reactive protein, HbA1c haemoglobin A1c, LDH lactate dehydrogenase, PIVKA-II protein induced by vitamin K absence or antagonists-II, PT prothrombin time, RBC red blood cell count, T.Bil total bilirubin, T.CHO total cholesterol, TG triglyceride, TP total protein, UA uric acid, WBC white blood cell count